PRME - Prime Medicine Appoints Allan Reine M.D. as Chief Financial Officer | Benzinga
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company's Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years' experience in the biotechnology industry, Dr. Reine will be responsible for the company's financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company.
"I am delighted to welcome Allan to Prime Medicine. He brings tremendous financial, operational and leadership experience in the life sciences space, as well as a proven track record developing and implementing multi-pronged strategies to finance a diverse pipeline and broad platform," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. "We look forward to his many contributions as we advance our lead programs toward the clinic, leverage the modularity of our Prime Editing technology to address a wide range of diseases and, ultimately, execute on our vision of delivering the promise of one-time, curative genetic therapies to patients worldwide."
Prior to joining Prime Medicine, Dr. Reine was Chief Financial Officer at Foghorn Therapeutics and, before that, at Pieris Pharmaceuticals. Dr. Reine also serves as Chairman of the Board of ONK Therapeutics. Previously, Dr. Reine managed various healthcare portfolios primarily focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and ...